Should You Retain Exact Sciences Stock in Your Portfolio Now?
EXAS' solid focus on advancing new solutions bodes well for investors. However, a dull macroeconomic condition adds to the worry.
3 Top Cancer Biotechs to Keep An Eye On in 2025
If the cancer space appeals to you, it's time to consider stocks like Novartis, Exact Sciences and Monte Rosa.
Exact Sciences: A Strong Q4 Reveals Signs Of A Potential Inflection Point
Exact Sciences posted strong Q4 revenue growth but faced a significant EPS miss due to an $838M impairment charge from the Thrive acquisition. Despite the negative market reaction, Exact's core business shows momentum, with strong demand for Cologuard and a solid cash position of $1.04B. The company has ambitious 2025 revenue guidance and expects new product launches to drive growth, aiming for sustained profitability and long-term value.
EXAS Q4 Loss Narrower Than Expected, Stock Falls, Revenues Up Y/Y
Exact Sciences' fourth-quarter 2024 performance benefits from the robust momentum in Cologuard adoption.
Exact Sciences Corporation (EXAS) Q4 2024 Earnings Call Transcript
Exact Sciences Corporation (NASDAQ:EXAS ) Q4 2024 Earnings Conference Call February 19, 2025 5:00 PM ET Company Participants Derek Leckow - Vice President, Investor Relations Kevin Conroy - Chairman and Chief Executive Officer Aaron Bloomer - Chief Financial Officer Brian Baranick - General Manager, Precision Oncology Conference Call Participants Catherine Schulte - Baird Doug Schenkel - Wolfe Research Tycho Peterson - Jefferies Matt Sykes - Goldman Sachs Dan Brennan - TD Cowen Jack Meehan - Nephron Research Andrew Brackmann - William Blair Patrick Donnelly - Citi Vijay Kumar - Evercore ISI Subu Nambi - Guggenheim Securities Puneet Souda - Leerink Partners Dan Leonard - UBS Bill Bonello - Craig Hallum Sung Ji Nam - Scotiabank Eve Burstein - Bernstein Research Andrew Cooper - Raymond James Kyle Mikson - Canaccord Operator Good day, everyone, and welcome to the Exact Sciences Fourth Quarter 2024 Earnings Call. Today's call is being recorded.
Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates
Exact Sciences (EXAS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.27 per share a year ago.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Exact Sciences (EXAS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Exact Sciences Sparks Analyst Optimism Amid Competitive Multi-Cancer Test Market
On Sunday, Exact Sciences Corp EXAS reported preliminary fiscal year 2024 sales of $2.76 billion, up 10% year-over-year, compared to consensus of $2.74 billion.
Should Exact Sciences Stock Stay in Your Portfolio Right Now?
EXAS' solid focus on expanding its lead Cologuard test and advancing new solutions bodes well for investors.
Exact Sciences Corporation (EXAS) Annual Evercore ISI HealthCONx Healthcare Conference (Transcript)
Exact Sciences Corporation (NASDAQ:EXAS ) Annual Evercore ISI HealthCONx Healthcare Conference December 4, 2024 7:30 AM ET Company Participants Kevin Conroy - CEO Aaron Bloomer - CFO Conference Call Participants Vijay Kumar - Evercore Vijay Kumar Great. Thanks everyone for joining us this morning.
